Filing Details
- Accession Number:
- 0001127602-22-020673
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-08-08 16:02:47
- Reporting Period:
- 2022-08-04
- Accepted Time:
- 2022-08-08 16:02:47
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1492422 | Apellis Pharmaceuticals Inc. | APLS | Pharmaceutical Preparations (2834) | 271537290 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1856078 | Jeffrey Mark Delong | C/O Apellis Pharmaceuticals, Inc. 100 Fifth Avenue, 3Rd Floor Waltham MA 02451 | Senior Vice President | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2022-08-04 | 10,000 | $15.52 | 39,250 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2022-08-04 | 5,000 | $59.50 | 34,250 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2022-08-04 | 5,000 | $62.00 | 29,250 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2022-08-04 | 10,000 | $0.00 | 10,000 | $15.52 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 15,000 | 2028-02-04 | No | 4 | M | Direct |
Footnotes
- This is a scheduled exercise and sale from an established 10B5-1 trading plan.
- This stock option will vest as to 25% of the shares underlying the options on the first anniversary of the grant date, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to continued service.
Billionaire Hedge Funds
